A
Autolus Therapeutics plc (AUTL)
NMS – Real vaqt narxi. Valyuta: USD
1.21
-0.08 (-6.20%)
Yopilishda: Mar 27, 2026, 4:00 PM EDT
1.22
+0.01 (0.83%)
Bozordan keyin: Mar 27, 2026, 7:59 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
NMS – Real vaqt narxi. Valyuta: USD
1.21
-0.08 (-6.20%)
Yopilishda: Mar 27, 2026, 4:00 PM EDT
1.22
+0.01 (0.83%)
Bozordan keyin: Mar 27, 2026, 7:59 PM EDT
Autolus Therapeutics plc, klinik bosqichdagi biofarmatsevtika kompaniyasi, Buyuk Britaniyada va xalqaro miqyosda saraton va otoimmün kasalliklarni davolash uchun T-hujayrali terapiyalarni ishlab chiqadi. Kompaniyaning klinik bosqichdagi dasturlari quyidagilarni o'z ichiga oladi: o'tkir limfoblastik leykoz (OLL) kattalar bemorlarini davolash uchun 1b/2-bosqich klinik sinovida bo'lgan CD19-ga yo'naltirilgan dasturlashtirilgan T-hujayrali tadqiqot terapiyasi bo'lgan obecabtagene autoleucel (AUTO1); takrorlanuvchi yoki refrakter OLL bilan kasallangan bolalar bemorlarida 1-bosqich klinik sinovida bo'lgan AUTO1/22; TRBC1 va TRBC2 ga yo'naltirilgan periferik T-hujayrali limfomani davolash uchun dasturlashtirilgan T-hujayrali tadqiqot terapiyasi bo'lgan AUTO4; neyroblastomani davolash uchun ishlab chiqilayotgan GD2 ga yo'naltirilgan dasturlashtirilgan T-hujayrali tadqiqot terapiyasi bo'lgan AUTO6NG; va ko'p miyelomani davolash uchun mahsulot nomzodi bo'lgan AUTO8. Kompaniya periferik T-hujayrali limfomani davolash uchun TRBC2 ga yo'naltirilgan preklinik dasturlashtirilgan T-hujayrali mahsulot nomzodi bo'lgan AUTO5ni ishlab chiqishga qaratilgan. Kompaniya 2014-yilda tashkil etilgan va Buyuk Britaniyaning London shahrida joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Christian Martin Itin Ph.D. | CEO & Director |
| Dr. Christopher Williams | Chief Business Officer |
| Dr. Martin Pule M.D., MBBS | Founder, Senior VP & Chief Scientific Officer |
| Dr. Matthias Will M.D. | Senior VP & Chief Development Officer |
| Mr. Alex Driggs | Senior VP of Legal Affairs & General Counsel and Secretary |
| Mr. Christopher Vann | Senior VP & COO |
| Mr. Patrick McIlvenny | Senior VP of Finance, Chief Accounting Officer & Principal Accounting Officer |
| Mr. Robert F. Dolski | Senior VP & CFO |
| Ms. Miranda Neville | Chief Technology Officer |
| Ms. Olivia Manser | Director of Investor Relations |
| Sana | Turi | Hujjat |
|---|---|---|
| 2025-12-02 | 8-K | autl-20251201.htm |
| 2025-11-18 | S-8 | d813559ds8.htm |
| 2025-08-12 | 8-K | autl-20250812.htm |
| 2025-06-27 | 8-K | autl-20250626.htm |
| 2025-06-02 | 8-K | autl-20250602.htm |
| 2025-05-30 | 8-K | d908343d8k.htm |
| 2025-05-13 | CORRESP | filename1.htm |
| 2025-05-08 | S-1 | d938913ds1.htm |
| 2025-04-23 | 8-K | autl-20250423.htm |
| 2025-04-03 | 8-K | d945856d8k.htm |